|  |  |  |
| --- | --- | --- |
| **INNOVATION FUNDING PROPOSAL FORM GUIDANCE – Maximum submission £100,000** | | |
| **Completing the proposal form and document control** | * **DEADLINE FOR SUBMISSION 24/06/2024 CLOSE OF PLAY** * Only forms completed in entirety will be considered for further evaluation. * Separate submissions should be made for each individual project/programme that are being requested * **Please note we cannot accept capital funding bids** * Please submit your completed proposal form (including any supporting evidence) to: tanis.barnett1@nhs.net | |
| **Assessment Principles** | **Innovation funding - The innovation funding confirmed should be used in line with the following parameters:**   1. Funding is to **implement, retain** or **scale up new innovations**   We define an innovation as “a service, process or product that is new or applied in a way that is new to the NHS or Cancer Alliance, which **significantly improves the quality of health and care** wherever it is applied”. **Examples include but are not limited to:**   * Tools to support Primary Care Records to identify patients with cancer symptoms/risk factors, including digital and AI. * Innovations to improve pathway efficiencies with the aim to reduce waiting times, treatment times and unnecessary referrals * Rule in/out tests for cancer. * Digital supported triage and workflow management. * Digital tools to support imaging networks. * Digital innovations to improve patient self-management * Tools that enable remote monitoring of patients.  1. The innovation **must support one of the three delivery plan aims:**  * Continue to reduce the number of patients waiting over 62 days * Meet the cancer faster diagnosis standard so that 75% of patients who have been urgently referred by their GP for suspected cancer are diagnosed or have cancer ruled out within 28 days * Increase the percentage of cancers diagnosed at stage 1 and 2 in line with the 75% early diagnosis ambition by 2028   Each proposal should be aligned with the overarching principles:   |  |  |  |  | | --- | --- | --- | --- | | Value for Money | Enabling Change | Reducing Variation | Savings and Efficiencies | | Consolidating Resources | Learning from and for Others | Long-lasting Impact and Impact on: | | | Beyond Hospital Care | Workforce | | Views of People Affected by Cancer | Scale of Effect vs Investment | Patient Outcomes and Experience | Patient Waiting Times | | |
| **Each proposal will be scored on responses to each question on a scale of:**  **0 - Poor, 1 - Adequate, 2 - Good, 3 - Excellent**  **They will then be weighed against the criteria and critical success factors:**   * **Readiness to deliver** * **Wider stakeholder engagement and support** * **Alignment to LSC Cancer Strategy and Delivery Plan** | **SCORE /45**  **WEIGHT /33** |
| **TOTAL FUNDS** |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **INNOVATION FUNDING PROPOSAL FORM** | | | | | | | | | | | |
| **SECTION 1: INFORMATION** | | | | | | | | | | | |
| **1.1** | **Project / Programme Manager** | |  | | | | | | | | |
| **1.2** | **Lead Organisation Name** | |  | | | | | | | | |
| **1.3** | **SRO for Project from Lead Organisation** | |  | | | | | | | | |
| **1.4** | **Clinical Lead** | |  | | | | | | | | |
| **1.5** | **Finance Lead (if applicable)** | |  | | | | | | | | |
| **1.6** | **Digital Lead for Project (if applicable)** | |  | | | | | | | | |
| **1.7** | **Date Submitted** | | / / | | | | | | | | |
| **SECTION 2: INVESTMENT CASE INFORMATION** | | | | | | | | | | | |
| **2.1** | **Title of Scheme/Project for this funding proposal** | |  | | | | | | | | |
| **2.2** | **Has this scheme been previously funded from any other funding stream?** | |  | | | | | | | | |
| **2.3** | **Anticipated work project/scheme start date** (*month and year)* | |  | | | | | | | | |
| **2.4** | **How much funding are you requesting from the LSC innovation fund in total? Indicate other sources of funding if not 100% for scheme/project** | |  | | | | | | | | |
| **SECTION 3: INVESTMENT CASE OUTLINE** | | | | | | | | | | | |
| **3.1** | **EXECUTIVE SUMMARY - What is the specific scope and content of the proposed project/scheme?**  ***(Maximum 200 words)*** | | | | | | | | | | |
|  | | | | | | |  | | | |
| **3.2** | **Please provide 3 problem statements that your project seeks to resolve.**  *These should be in the format; ‘We have noticed that…which is causing…which has the consequence of…which leads to…’.* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **3.3** | **Please provide an overview of the context within which the investment will be made.**  ***(Maximum 400 words)*** *i.e., the organisational strategy, work programme, service, project, or operation, which the investment supports. Please provide the compelling reasons for investment in the required services and why investment has not been possible to date?* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **3.4** | **Why is this a priority?**  ***(Maximum 400 words)*** *The innovation must support one of the three prioritised Delivery Plan aims: 1. Continue to reduce the number of patients waiting over 62 days. 2. Meet the cancer faster diagnosis standard so that 75% of patients who have been urgently referred by their GP for suspected cancer are diagnosed or have cancer ruled out withing 28 days. 3. Increase the percentage of cancers diagnosed at stage 1 and 2 in line with the 75% early diagnosis ambition by 2028. Please also consider****:***   * *What is the service impact of the proposed project outcomes?* * *How will the programme contribute to wider transformation across your locality and LSC?* * *What opportunities are there for other localities and LSC transformation initiatives to collaborate with this project, either by providing enablers, by accessing/using the digital technology output or by replicating the approach?* | | | | | | | | | | |
|  | | | | | | | | | |  |
| **SECTION 4: DELIVERY, BENEFITS AND ENGAGEMENT** | | | | | | | | | | | |
| **4.1** | **Project/Scheme Benefits.**  ***(Maximum 400 words)*** *Please indicate the benefits/outcome measures associated with your innovation fund bid, summarise the benefits- financial (cash and non-cash releasing and qualitative). You can add in a benefits map showing the impact of the project, linked to outcome benefits and to overall objectives. Please indicate when benefits are to be initially realised and* ***how will success be defined?*** | | | | | | | | | | |
|  | | | | | | | | |  | |
| **4.2** | **Patient, Carer, Citizen Engagement and Key Benefits.**  ***(Maximum 400 words)*** *Please outline what planned level of engagement will take place to involve patients and carers. Please also detail the* ***benefits*** *of this proposal to the Patient and Carer community.* | | | | | | | | | | |
|  |  | | | | | | |  | | | |
| **4.3** | **Project/Scheme Milestones/Timeline**  ***(Maximum 200 words)*** *Please indicate the milestones for the project and the anticipated go live date.* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **4.4** | **Please describe the delivery mechanisms and governance in place to manage this scheme? *(Maximum 200 words)*** *What project management methodology and process is in place to support delivery of the programme? What business case approval/validation has this scheme been through? What resources are required (equipment and people)? Please describe the governance structure and arrangements that will be in place to support this scheme.* | | | | | | | | | | |
|  | | | | | | | | | |  |
| **4.6** | **Savings and Efficiencies**  ***(Maximum 200 words)*** *Where possible provide an estimate of the potential cost savings and efficiencies that might arise from the proposal (savings – where costs can be removed; efficiencies – where demand can be mitigated). If it is not possible to quantify these, then provide a narrative to explain the logic that gives rise to an expectation of the savings and\or efficiencies.* | | | | | | | | | | |
|  | | | | | | | |  | | |
| **4.7** | **Key Risks**  *Please provide adequate information to enable reviewers to understand the level and likelihood of risk and how it is to be mitigated. Please list any risks to delivery, for example if the spend is dependent on organisational merger, or estates investment, clinical implications etc.* | | | | | | | | | | |
| Risk | Likelihood | | Impact | | Score | Mitigation | | | | |
|  |  | |  | |  |  | | | | |
|  |  | | |  |  |  | | | | |
|  |  | | |  |  |  | | | | |
|  | | | | | | |  | | | |
| **4.8** | **Please provide evidence that the proposal has wider stakeholder support**  ***(Maximum 200 words)*** *What system/sector engagement has been undertaken?* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **4.9** | **Clinical Engagement and Review**  ***(Maximum 200 words)*** *What clinical engagement has been undertaken, and how has this influenced the design of the programme including how this links to governance and prioritisation?* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **6** | **FINANCES** | | | | | | | | | | |
| **6.1** | **Proposal Finances**  *The overall funding asks, by scheme or programme.* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **6.2** | **SUSTAINABILITY: The Innovation Fund is non-recurrent funding. Please provide evidence that any revenue and capital refresh consequence will be addressed.**  ***(Maximum 200 words)*** *What plans are there for maintenance and support over the lifecycle of the product, product refresh and replacement at the end of the lifecycle?* | | | | | | | | | | |
|  | | | | | | |  | | | |
| **6.3** | **Revenue Funding/Impact (if applicable)**  ***(Maximum 200 words)*** Please confirm which organisation has committed to meeting the revenue costs | | | | | | | | | | |
|  | | | | | | |  | | | |